A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)

PHASE2CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

May 4, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

December 10, 2022

Conditions
Plaque Psoriasis
Interventions
DRUG

AUR101

Oral ROR-gamma inverse agonist

DRUG

Placebo

Placebo

Trial Locations (25)

10012

The Dermatology Specialists, New York

10075

Sadick Research Group, New York

19103

Paddington Testing Co, Inc, Philadelphia

32720

Accel Research Sites - Deland CRU, DeLand

33012

Direct Helpers Research Center, Hialeah

33016

Abys New Generation Research Inc., Hialeah

33027

FXM Clinical Research Miramar LLC, Miramar

33146

Skin Research Institute, Coral Gables

33172

Lenus Research & Medical Group, LLC, Sweetwater

33175

FXM Clinical Research Miami LLC, Miami

33179

Floridian Reserach, Miami

33308

FXM Clinical Research Fort Lauderdale, Fort Lauderdale

33511

Moore Clinical Research, Inc., Brandon

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

48706

Great Lakes Research Group, Inc, Bay City

64506

Medisearch Clinical Trials, Saint Joseph

72758

Northwest AR Clinical Trials Center, Rogers

72916

Johnson Dermatology, Fort Smith

75230

Dermatology Treatment & Research Center, Dallas

77598

Center for Clinical Studies Ltd., LLP., Webster

90045

Dermatology Research Associates, Los Angeles

90404

Clinical Science Institute, Santa Monica

91403

Unison Clinical Trials, Sherman Oaks

92123

University Clinical Trials, Inc., San Diego

92708

First OC Dermatology, Fountain Valley

All Listed Sponsors
lead

Aurigene Discovery Technologies Limited

INDUSTRY